Cargando…

Risk stratification of postoperative cardiopulmonary toxicity after trimodality therapy for esophageal cancer

PURPOSE/OBJECTIVE: Postoperative toxicity for esophageal cancer impacts patient quality of life and potentially overall survival (OS). We studied whether patient and toxicity parameters post-chemoradiation therapy predict for post-surgical cardiopulmonary total toxicity burden (CPTTB) and whether CP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kowalchuk, Roman O., Spears, Grant M., Morris, Lindsay K., Owen, Dawn, Yoon, Harry H., Jethwa, Krishan, Chuong, Michael D., Ferris, Matthew J., Haddock, Michael G., Hallemeier, Christopher L., Wigle, Dennis, Lin, Steven H., Merrell, Kenneth W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948243/ https://www.ncbi.nlm.nih.gov/pubmed/36845682 http://dx.doi.org/10.3389/fonc.2023.1081024

Ejemplares similares

Multi-institutional Evaluation of Curative Intent Chemoradiotherapy for Patients With Clinical T1N0 Esophageal Adenocarcinoma
por: Deng, Wei, et al.
Publicado: (2020)

Research on Anal Squamous Cell Carcinoma
por: Jethwa, Krishan R., et al.
Publicado: (2021)

Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes
por: Jethwa, Krishan R., et al.
Publicado: (2018)

Proton beam radiotherapy for esophagus cancer: state of the art
por: Gergelis, Kimberly R., et al.
Publicado: (2020)

Clinical Implementation of Preoperative Short-Course Pencil Beam Scanning Proton Therapy for Patients With Rectal Cancer
por: Jeans, Elizabeth B., et al.
Publicado: (2020)

A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer
por: Routman, David M., et al.
Publicado: (2019)

Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma
por: Goense, Lucas, et al.
Publicado: (2018)

ASO Author Reflections: Predicting Early Recurrence After Trimodality Therapy for Esophageal Adenocarcinoma
por: Goense, Lucas, et al.
Publicado: (2018)

Assessment of a collaborative treatment model for trimodal management of esophageal cancer
por: Udelsman, Brooks V., et al.
Publicado: (2023)

Radiation dose mapping and anastomotic complications after trimodality therapy for esophageal cancers
por: Bang, Andrew, et al.
Publicado: (2019)

Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience
por: Jethwa, Krishan R., et al.
Publicado: (2021)

Trimodality Therapy vs Definitive Chemoradiation in Older Adults With Locally Advanced Esophageal Cancer
por: Gaber, Charles E, et al.
Publicado: (2022)

Personalized trimodal prehabilitation for gastrectomy
por: Bausys, Augustinas, et al.
Publicado: (2020)

Trimodality therapy for esophageal cancer: The role of surgical and radiation treatment parameters in the development of anastomotic complications
por: Alfaifi, Salem, et al.
Publicado: (2021)

Commentary: Adjuvant chemotherapy after trimodal therapy for esophageal carcinoma: A bitter pill to swallow
por: Du, Valerie X., et al.
Publicado: (2020)

Immunohistochemical analyses of paraffin-embedded sections after primary surgery or trimodality treatment in esophageal carcinoma
por: Igbo, Benjamin Terfa, et al.
Publicado: (2022)

Clinical outcomes of pancoast tumors treated with trimodality therapy
por: Lin, Tami Yu-Yu, et al.
Publicado: (2021)

Trimodal Therapy in Esophageal Squamous Cell Carcinoma: Role of Adjuvant Therapy Following Neoadjuvant Chemoradiation and Surgery
por: Li, Xiaokun, et al.
Publicado: (2022)

‘CROSS’-ing into the ‘Real World’: a retrospective cohort study of patients receiving trimodality and bimodality therapy for esophageal cancer
por: Higgins, Luke M., et al.
Publicado: (2023)

Predictors of relapse and evaluation of the role of postoperative radiation therapy in a modern series of patients with surgically resected stage III (N2) non–small cell lung cancer
por: Breen, William G., et al.
Publicado: (2016)

Comparing Oncologic Outcomes and Toxicity for Combined Modality Therapy vs. Carbon-Ion Radiotherapy for Previously Irradiated Locally Recurrent Rectal Cancer
por: Jeans, Elizabeth B., et al.
Publicado: (2023)

Prognostic factors associated with (18)FDG-PET/CT in esophageal squamous cell carcinoma after trimodality treatment
por: Feng, Wei-Hsiang, et al.
Publicado: (2022)

Trimodal therapy in squamous cell carcinoma of the esophagus
por: Matuschek, C, et al.
Publicado: (2011)

Bipolar disorder: Trimodal age‐at‐onset distribution
por: Bolton, Sorcha, et al.
Publicado: (2020)

Anaplastic thyroid cancer: outcomes of trimodal therapy
por: Houlihan, Orla A., et al.
Publicado: (2021)

Trimodal Therapy: A Tumor Vascular‐Targeted Interlocking Trimodal Nanosystem That Induces and Exploits Hypoxia (Adv. Sci. 8/2018)
por: Luan, Xin, et al.
Publicado: (2018)

Multi-institutional Comparison of Intensity Modulated Photon Versus Proton Radiation Therapy in the Management of Squamous Cell Carcinoma of the Anus()()
por: Mohiuddin, Jahan J., et al.
Publicado: (2021)

Definitive re-irradiation of locally recurrent esophageal cancer after trimodality therapy in patients with a poor performance status
por: W. Kim, Daniel, et al.
Publicado: (2020)

Time to Surgery for Patients with Esophageal Cancer Undergoing Trimodal Therapy in Ontario: A Population-Based Cross-Sectional Study
por: Hanna, Nader M., et al.
Publicado: (2022)

Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9
por: Kowalchuk, Roman O., et al.
Publicado: (2021)

Trimodality therapy in variant urothelial carcinoma: choose wisely
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2017)

Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy
por: Ozyurt, Hazan, et al.
Publicado: (2023)

The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer
por: Russell, Christopher M., et al.
Publicado: (2016)

Role of FDG-PET/CT in prediction of pathological tumor response and survival after trimodality therapy for esophageal squamous cell carcinoma
por: Hamai, Yoichi, et al.
Publicado: (2015)

Ion therapy within the trimodal management of superior sulcus tumors: the INKA trial
por: Hauswald, Henrik, et al.
Publicado: (2015)

Evaluation of Failure Patterns Using Trimodality in Non-Small Cell Lung Cancer
por: Patel, Shilpen, et al.
Publicado: (2011)

Long-term Clinical Outcomes and Safety Profile of SBRT for Centrally Located NSCLC
por: Arnett, Andrea L.H., et al.
Publicado: (2019)

Early results of a trimodality treatment for superior sulcus tumors
por: Łapiński, Mariusz, et al.
Publicado: (2014)

Developing Hollow-Channel Gold Nanoflowers as Trimodal Intracellular Nanoprobes
por: Ye, Sunjie, et al.
Publicado: (2018)

Trimodal Race Model Inequalities in Multisensory Integration: I. Basics
por: Colonius, Hans, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r1rqojpu1t0bp72f8e124q5fse